Abiomed Inc (NASDAQ:ABMD)
| 181.69 Delayed Data As of 4:00pm ET |  -7.53 / -3.98%Today’s Change | 155.02 Today|||52-Week Range 364.31 | -44.10% Year-to-Date |
Latest ABMD News | Press Releases
| Is Abiomed a Bad-News Buy Right Now? Dec 04 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 189.22 |
| Today’s open | 189.30 |
| Day’s range | 179.54 - 189.83 |
| Volume | 764,077 |
| Average volume (3 months) | 726,253 |
| Market cap | $8.6B |
Data as of 4:00pm ET, 12/09/2019
Growth & Valuation
| Earnings growth (last year) | +127.01% |
| Earnings growth (this year) | -19.93% |
| Earnings growth (next 5 years) | +23.00% |
| Revenue growth (last year) | +29.59% |
| P/E ratio | 37.9 |
| Price/Sales | 17.13 |
| Price/Book | 9.15 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| WSTWest Pharmaceutical ... | -2.74 | -1.86% |
| HAEHaemonetics Corp | -3.76 | -3.10% |
| PENPenumbra Inc | -6.60 | -3.93% |
| PODDInsulet Corp | -3.30 | -1.79% |
Data as of 6:30pm ET, 12/09/2019
Financials
| Next reporting date | January 30, 2020 |
| EPS forecast (this quarter) | $1.09 |
| Annual revenue (last year) | $769.4M |
| Annual profit (last year) | $259.0M |
| Net profit margin | 33.66% |
Profile
Sector Health Technology |
Industry Medical Specialties |
No executives to display |
Corporate headquarters Danvers, Massachusetts |
Forecasts
